
Katharine M Irvine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5609735/publications.pdf Version: 2024-02-01



KATHADINE M IDVINE

#	Article	IF	CITATIONS
1	The regulated retrotransposon transcriptome of mammalian cells. Nature Genetics, 2009, 41, 563-571.	21.4	731
2	Histone deacetylases as regulators of inflammation and immunity. Trends in Immunology, 2011, 32, 335-343.	6.8	456
3	The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nature Genetics, 2009, 41, 553-562.	21.4	408
4	The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology, 2014, 59, 1393-1405.	7.3	344
5	Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E944-53.	7.1	332
6	Tiny RNAs associated with transcription start sites in animals. Nature Genetics, 2009, 41, 572-578.	21.4	327
7	<i>Gpnmb</i> Is Induced in Macrophages by IFN-Î ³ and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses. Journal of Immunology, 2007, 178, 6557-6566.	0.8	191
8	The Mononuclear Phagocyte System: The Relationship between Monocytes and Macrophages. Trends in Immunology, 2019, 40, 98-112.	6.8	188
9	Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. Journal of Leukocyte Biology, 2010, 87, 1103-1114.	3.3	163
10	ADGRE1 (EMR1, F4/80) Is a Rapidly-Evolving Gene Expressed in Mammalian Monocyte-Macrophages. Frontiers in Immunology, 2018, 9, 2246.	4.8	149
11	Acute lipopolysaccharide priming boosts inflammasome activation independently of inflammasome sensor induction. Immunobiology, 2012, 217, 1325-1329.	1.9	140
12	Rasputin, more promiscuous than ever: a review of G3BP. International Journal of Developmental Biology, 2004, 48, 1065-1077.	0.6	133
13	Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Frontiers in Immunology, 2019, 10, 293.	4.8	116
14	Phenotypic impacts of CSF1R deficiencies in humans and model organisms. Journal of Leukocyte Biology, 2020, 107, 205-219.	3.3	97
15	<i>Salmonella</i> employs multiple mechanisms to subvert the TLRâ€inducible zincâ€mediated antimicrobial response of human macrophages. FASEB Journal, 2016, 30, 1901-1912.	0.5	91
16	Data-driven normalization strategies for high-throughput quantitative RT-PCR. BMC Bioinformatics, 2009, 10, 110.	2.6	86
17	Histone Deacetylase 7 Promotes Toll-like Receptor 4-dependent Proinflammatory Gene Expression in Macrophages. Journal of Biological Chemistry, 2013, 288, 25362-25374.	3.4	81
18	Underappreciation of nonâ€alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Internal Medicine Journal, 2018, 48, 144-151.	0.8	80

KATHARINE M IRVINE

#	Article	IF	CITATIONS
19	The FANTOM web resource: from mammalian transcriptional landscape to its dynamic regulation. Genome Biology, 2009, 10, R40.	9.6	73
20	A CSFâ€l receptor kinase inhibitor targets effector functions and inhibits proâ€inflammatory cytokine production from murine macrophage populations. FASEB Journal, 2006, 20, 1921-1923.	0.5	69
21	Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages. Journal of Leukocyte Biology, 2009, 85, 278-288.	3.3	69
22	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. British Journal of Clinical Pharmacology, 2016, 81, 210-222.	2.4	69
23	Macrophage Activation and Differentiation Signals Regulate Schlafen-4 Gene Expression: Evidence for Schlafen-4 as a Modulator of Myelopoiesis. PLoS ONE, 2011, 6, e15723.	2.5	67
24	<scp>ELF</scp> score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver International, 2015, 35, 1673-1681.	3.9	60
25	A Transgenic Line That Reports CSF1R Protein Expression Provides a Definitive Marker for the Mouse Mononuclear Phagocyte System. Journal of Immunology, 2020, 205, 3154-3166.	0.8	59
26	Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. World Journal of Gastroenterology, 2014, 20, 17851-17862.	3.3	57
27	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and Atâ€Risk Populations in Primary Care. Hepatology Communications, 2018, 2, 897-909.	4.3	54
28	CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites. JCI Insight, 2016, 1, e86914.	5.0	53
29	The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver International, 2016, 36, 370-377.	3.9	51
30	Update of the FANTOM web resource: from mammalian transcriptional landscape to its dynamic regulation. Nucleic Acids Research, 2011, 39, D856-D860.	14.5	49
31	Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?. Internal Medicine Journal, 2014, 44, 865-872.	0.8	47
32	Differential Effects of CpG DNA on IFN-β Induction and STAT1 Activation in Murine Macrophages versus Dendritic Cells: Alternatively Activated STAT1 Negatively Regulates TLR Signaling in Macrophages. Journal of Immunology, 2007, 179, 3495-3503.	0.8	44
33	CSF1R-dependent macrophages control postnatal somatic growth and organ maturation. PLoS Genetics, 2021, 17, e1009605.	3.5	44
34	Peripheral Blood Monocyte Gene Expression Profile Clinically Stratifies Patients With Recent-Onset Type 1 Diabetes. Diabetes, 2012, 61, 1281-1290.	0.6	43
35	Portal, but not lobular, macrophages express matrix metalloproteinaseâ€9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver International, 2013, 33, 569-579.	3.9	42
36	PU.1 and ICSBP control constitutive and IFN-Î ³ -regulated Tlr9 gene expression in mouse macrophages. Journal of Leukocyte Biology, 2007, 81, 1577-1590.	3.3	41

KATHARINE M IRVINE

#	Article	IF	CITATIONS
37	Multimorbidity and polypharmacy in diabetic patients with NAFLD. Medicine (United States), 2017, 96, e6761.	1.0	39
38	Functions of macrophage colony-stimulating factor (CSF1) in development, homeostasis, and tissue repair. Seminars in Immunology, 2021, 54, 101509.	5.6	39
39	Ascites Bacterial Burden and Immune Cell Profile Are Associated with Poor Clinical Outcomes in the Absence of Overt Infection. PLoS ONE, 2015, 10, e0120642.	2.5	38
40	Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. BMC Gastroenterology, 2014, 14, 97.	2.0	37
41	Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury. Fibrogenesis and Tissue Repair, 2015, 8, 19.	3.4	36
42	Fragmentation of tissue-resident macrophages during isolation confounds analysis of single-cell preparations from mouse hematopoietic tissues. Cell Reports, 2021, 37, 110058.	6.4	36
43	Selective induction of the Notch ligand Jaggedâ€l in macrophages by soluble egg antigen from <i>Schistosoma mansoni</i> involves ERK signalling. Immunology, 2009, 127, 326-337.	4.4	35
44	Recombinant <scp>W</scp> nt3a and <scp>W</scp> nt5a elicit macrophage cytokine production and tolerization to microbial stimulation via <scp>T</scp> ollâ€kike receptor 4. European Journal of Immunology, 2014, 44, 1480-1490.	2.9	35
45	Analysis of the impact of CSF-1 administration in adult rats using a novel <i>Csf1r</i> -mApple reporter gene. Journal of Leukocyte Biology, 2020, 107, 221-235.	3.3	35
46	Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight, 2018, 3, .	5.0	35
47	Medicationâ€Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. Hepatology Communications, 2019, 3, 620-631.	4.3	33
48	Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation. PLoS ONE, 2016, 11, e0157771.	2.5	33
49	Macrophage colony-stimulating factor increases hepatic macrophage content, liver growth, and lipid accumulation in neonatal rats. American Journal of Physiology - Renal Physiology, 2018, 314, G388-G398.	3.4	32
50	The combination of gene perturbation assay and ChIP-chip reveals functional direct target genes for IRF8 in THP-1 cells. Molecular Immunology, 2010, 47, 2295-2302.	2.2	31
51	Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. Metabolism: Clinical and Experimental, 2018, 78, 80-94.	3.4	30
52	Development of a DNA barcode tagging method for monitoring dynamic changes in gene expression by using an ultra high-throughput sequencer. BioTechniques, 2008, 45, 95-97.	1.8	29
53	Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers. PLoS ONE, 2016, 11, e0167001.	2.5	29
54	Analysis of homozygous and heterozygous Csf1r knockout in the rat as a model for understanding microglial function in brain development and the impacts of human CSF1R mutations. Neurobiology of Disease, 2021, 151, 105268.	4.4	29

#	Article	IF	CITATIONS
55	Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. American Journal of Pathology, 2016, 186, 524-538.	3.8	28
56	Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. BMC Gastroenterology, 2016, 16, 114.	2.0	25
57	Osteal macrophages support osteoclast-mediated resorption and contribute to bone pathology in a postmenopausal osteoporosis mouse model. Journal of Bone and Mineral Research, 2021, 36, 2214-2228.	2.8	25
58	Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World Journal of Gastroenterology, 2017, 23, 7321-7331.	3.3	25
59	Optimising care of patients with chronic disease: patientâ€oriented education may improve disease knowledge and selfâ€management. Internal Medicine Journal, 2017, 47, 952-955.	0.8	23
60	Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-Î ² -induced collagen expression in hepatic stellate cells. Scientific Reports, 2019, 9, 8541.	3.3	23
61	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. JHEP Reports, 2022, 4, 100386.	4.9	22
62	Inhibitors of class I histone deacetylases attenuate thioacetamideâ€induced liver fibrosis in mice by suppressing hepatic type 2 inflammation. British Journal of Pharmacology, 2019, 176, 3775-3790.	5.4	21
63	Predicting Liverâ€Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests. Hepatology Communications, 2022, 6, 728-739.	4.3	20
64	Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-8.	1.9	17
65	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. Scientific Reports, 2021, 11, 2858.	3.3	16
66	Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. Hepatology Communications, 2020, 4, 1279-1292.	4.3	15
67	The Mononuclear Phagocyte System of the Rat. Journal of Immunology, 2021, 206, 2251-2263.	0.8	15
68	Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians. International Journal for Equity in Health, 2020, 19, 27.	3.5	14
69	Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease. Internal Medicine Journal, 2016, 46, 420-426.	0.8	12
70	Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. Trials, 2017, 18, 339.	1.6	12
71	Transcriptomic Analysis of Rat Macrophages. Frontiers in Immunology, 2020, 11, 594594.	4.8	12
72	Treatment with a long-acting chimeric CSF1 molecule enhances fracture healing of healthy and osteoporotic bones. Biomaterials, 2021, 275, 120936.	11.4	11

KATHARINE M IRVINE

#	Article	IF	CITATIONS
73	Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. Journal of Diabetes and Its Complications, 2018, 32, 799-804.	2.3	10
74	Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores. Clinical Gastroenterology and Hepatology, 2020, 18, 710-718.e4.	4.4	10
75	Effectiveness of patientâ€oriented education and medication management intervention in people with decompensated cirrhosis. Internal Medicine Journal, 2020, 50, 1142-1146.	0.8	10
76	A kinase-dead <i>Csf1r</i> mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling. Development (Cambridge), 2022, 149, .	2.5	9
77	Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention. Internal Medicine Journal, 2013, 43, 1096-1102.	0.8	7
78	Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathogens, 2022, 18, e1010166.	4.7	7
79	Therapeutic potential of macrophage colony-stimulating factor in chronic liver disease. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	7
80	<scp>BMI</scp> But Not Stage or Etiology of Nonalcoholic Liver Disease Affects the Diagnostic Utility of Carbohydrateâ€Deficient Transferrin. Alcoholism: Clinical and Experimental Research, 2013, 37, 1771-1778.	2.4	6
81	Association between the fetal cerebroplacental ratio and biomarkers of hypoxia and angiogenesis in the maternal circulation at term. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 245, 198-204.	1.1	6
82	Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism. PLoS ONE, 2022, 17, e0261555.	2.5	6
83	Identifying areas of need relative to liver disease: geographic clustering within a health service district. Australian Health Review, 2017, 41, 407.	1.1	3
84	Towards collaborative management of nonâ€alcoholic fatty liver disease: a â€~realâ€world' pathway for fibrosis risk assessment in primary care. Internal Medicine Journal, 2022, 52, 1749-1758.	0.8	3
85	Epidemiology of ascites fluid infections in patients with cirrhosis in Queensland, Australia from 2008 to 2017. Medicine (United States), 2022, 101, e29217.	1.0	3
86	Liver repercussions of defective gut surveillance. Hepatology, 2012, 56, 1174-1177.	7.3	2
87	Expression profiling preâ€diabetic mice to uncover drugs with clinical application to type 1 diabetes. Clinical and Translational Immunology, 2015, 4, e41.	3.8	2
88	Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. Pharmaceuticals, 2021, 14, 1207.	3.8	1
89	Patientâ€oriented medication education intervention has longâ€term benefits for people with decompensated cirrhosis. Hepatology Communications, 2022, 6, 3281-3282.	4.3	1
90	The Impact of CAGE Data on Understanding Macrophage Transcriptional Biology. , 2009, , 227-243.		0

The Impact of CAGE Data on Understanding Macrophage Transcriptional Biology. , 2009, , 227-243. 90

#	Article	IF	CITATIONS
91	New Paradigms in the Histopathology of NAFLD. Current Hepatology Reports, 2014, 13, 81-87.	0.9	0
92	Response to ELF cutâ€off points: aetiology is also a relevant factor. Liver International, 2015, 35, 1921-1921.	3.9	0
93	Expression profiling feline peripheral blood monocytes identifies a transcriptional signature associated with type two diabetes mellitus. Veterinary Immunology and Immunopathology, 2017, 186, 1-8.	1.2	0
94	Reply. Hepatology Communications, 2019, 3, 1283-1284.	4.3	0